GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (STU:8CC) » Definitions » Cyclically Adjusted Book per Share

Cocrystal Pharma (STU:8CC) Cyclically Adjusted Book per Share : €40.93 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cocrystal Pharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cocrystal Pharma's adjusted book value per share for the three months ended in Mar. 2024 was €2.042. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €40.93 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Cocrystal Pharma's average Cyclically Adjusted Book Growth Rate was 14.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 15.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Cocrystal Pharma was 15.70% per year. The lowest was 10.10% per year. And the median was 12.75% per year.

As of today (2024-05-23), Cocrystal Pharma's current stock price is €1.69. Cocrystal Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €40.93. Cocrystal Pharma's Cyclically Adjusted PB Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cocrystal Pharma was 1.39. The lowest was 0.05. And the median was 0.25.


Cocrystal Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Cocrystal Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Cyclically Adjusted Book per Share Chart

Cocrystal Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 21.86 25.55 31.34 37.01

Cocrystal Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.14 34.43 38.99 37.01 40.93

Competitive Comparison of Cocrystal Pharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Cocrystal Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Cyclically Adjusted PB Ratio falls into.



Cocrystal Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cocrystal Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.042/131.7762*131.7762
=2.042

Current CPI (Mar. 2024) = 131.7762.

Cocrystal Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 13.164 100.560 17.251
201409 9.072 100.428 11.904
201412 15.853 99.070 21.087
201503 91.338 99.621 120.820
201506 90.783 100.684 118.818
201509 90.889 100.392 119.303
201512 79.763 99.792 105.327
201603 77.736 100.470 101.958
201606 75.901 101.688 98.359
201609 75.390 101.861 97.531
201612 48.905 101.863 63.267
201703 47.133 102.862 60.382
201706 44.998 103.349 57.375
201709 41.475 104.136 52.484
201712 44.027 104.011 55.780
201803 41.531 105.290 51.979
201806 38.669 106.317 47.929
201809 38.115 106.507 47.158
201812 23.567 105.998 29.298
201903 24.794 107.251 30.464
201906 24.322 108.070 29.657
201909 24.378 108.329 29.654
201912 7.899 108.420 9.601
202003 8.421 108.902 10.190
202006 7.573 108.767 9.175
202009 7.456 109.815 8.947
202012 7.353 109.897 8.817
202103 7.342 111.754 8.657
202106 8.660 114.631 9.955
202109 8.478 115.734 9.653
202112 8.450 117.630 9.466
202203 8.226 121.301 8.936
202206 5.753 125.017 6.064
202209 5.446 125.227 5.731
202212 4.587 125.222 4.827
202303 3.977 127.348 4.115
202306 3.146 128.729 3.220
202309 2.827 129.860 2.869
202312 2.378 129.419 2.421
202403 2.042 131.776 2.042

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Cocrystal Pharma  (STU:8CC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cocrystal Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.69/40.93
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cocrystal Pharma was 1.39. The lowest was 0.05. And the median was 0.25.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cocrystal Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma (STU:8CC) Business Description

Industry
Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma (STU:8CC) Headlines

No Headlines